Open Access

F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis and prognosis prediction of vascular tumors

  • Authors:
    • Won Woo Lee
    • Young So
    • Seo Young Kang
    • Min‑Kyung So
    • Haeryoung Kim
    • Hyun Woo Chung
    • Wan Seop Kim
    • Sang Eun Kim
  • View Affiliations

  • Published online on: May 17, 2017     https://doi.org/10.3892/ol.2017.6192
  • Pages: 665-672
  • Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The spectrum of vascular tumors ranges from hemangioma (HEM), to epithelioid hemangioendothelioma (EHE) and to angiosarcoma (AS). To the best of our knowledge, the usefulness of F‑18 fluorodeoxyglucose positron emission tomography (FDG‑PET) for vascular tumors has never been comprehensively studied. The present study investigated the usefulness of FDG‑PET for pathologically diagnosed vascular tumors. The present study included 26 patients with vascular tumor (male:female, 17:9; age, 60.9±14.4 years; 7 HEM, 6 EHE and 13 AS) who underwent FDG‑PET between January 2007 and May 2014 at the Seoul National University Bundang Hospital (Seongnam, Korea) and Konkuk University Medical Center, (Seoul, Korea). Representative FDG uptake was measured as the maximum standardized uptake value (SUVmax) over the lesion with the highest FDG uptake. Disease progression was clinically defined as the aggravation of known lesions or novel lesion development during follow‑up on computed tomography, magnetic resonance imaging, or FDG‑PET. FDG‑PET revealed multi‑organ involvement only in AS (6/13 [46.2%]), whereas HEM and EHE involved a single organ. Tumor SUVmax was significantly greater in AS (6.32±4.84) compared with EHE (3.10±2.68) and HEM (2.33±0.76) (P=0.0284). There was no difference in tumor SUVmax between HEM and EHE (P>0.05). Disease progression was primarily noticed in AS (9/13 [69.2%]). Only 1 patient with EHE (1/6=16.7%) and no patients with HEM (0/7=0%) experienced disease progression. Mortality was reported only in patients with AS (4/13 [30.8%]). Using the cutoff SUVmax of 3.0, the two‑year progression‑free survival rate of 14 patients with tumor SUVmax <3.0 (75.0%) was significantly higher compared with that of 12 patients with tumor SUVmax ≥3.0 (0%) (P=0.0053). In conclusion, FDG‑PET is useful for the differential diagnosis and prognosis prediction of vascular tumors.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 14 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lee WW, So Y, Kang SY, So MK, Kim H, Chung HW, Kim WS and Kim SE: F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis and prognosis prediction of vascular tumors. Oncol Lett 14: 665-672, 2017
APA
Lee, W.W., So, Y., Kang, S.Y., So, M., Kim, H., Chung, H.W. ... Kim, S.E. (2017). F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis and prognosis prediction of vascular tumors. Oncology Letters, 14, 665-672. https://doi.org/10.3892/ol.2017.6192
MLA
Lee, W. W., So, Y., Kang, S. Y., So, M., Kim, H., Chung, H. W., Kim, W. S., Kim, S. E."F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis and prognosis prediction of vascular tumors". Oncology Letters 14.1 (2017): 665-672.
Chicago
Lee, W. W., So, Y., Kang, S. Y., So, M., Kim, H., Chung, H. W., Kim, W. S., Kim, S. E."F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis and prognosis prediction of vascular tumors". Oncology Letters 14, no. 1 (2017): 665-672. https://doi.org/10.3892/ol.2017.6192